Drug Pipeline

Inclisiran sodium 300 mg Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
5
Active Studies
1
Recruiting
4
Phase 3
2
Top Sponsors
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-11 NCT06909565
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb…		 Trial sites expanded: 99 -> 102 locations
2026-06-02 NCT06909565
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb…		 Trial sites expanded: 96 -> 100 locations
Active Studies by Phase
Phase 4
1
Phase 3
4
Active Trials
NCT IDTitleConditionStatus
Phase 4
NCT06909565 Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb… Percutaneous Coronary Intervention Recruiting
Phase 3
NCT04765657 Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic… Hypercholesterolemia Active, Not Recruiting
NCT05360446 Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to… Coronary Artery Disease Active, Not Recruiting
NCT05030428 Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With… Atherosclerotic Cardiovascular Disease Active, Not Recruiting
NCT05739383 A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention… Primary Prevention of Atherosclerotic Cardiovascular Disease Active, Not Recruiting
Sponsors Running Inclisiran sodium 300 mg Trials
Novartis Pharmaceuticals (4) Duke University (1)
Disease Areas
Heart Disease (2) Coronary Artery Disease (1)
Get alerts when Inclisiran sodium 300 mg trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free